O ccasionally, a clinical study published in the medical literature captures the attention of the national media. Unfortunately, most health professionals, including pharmacists, first learn about the study from patients who ask how the new results might affect their therapy. From a clinical point of view, television or radio broadcasts are only marginally helpful, because they rarely cite the original source and often distill studies into brief sound bites (30 seconds or less), thus sensationalizing the most general results. Print media is usually more informative, but rarely provides detailed data.
The problem with this scenario is that the pharmacist is often forced into a reactive role, that is, he or shebeing unprepared -cannot take a proactive, educational position on the study in question. In addition, locating the study, digesting it in a timely manner, and then translating it into clinical practice are fraught with hurdles during a busy workday.
An important example of this situation occured in midsummer 2002, when a series of articles about the failure of combination estrogen-progestin hormone replacement therapy to prevent cardiovascular risk was published in JAMA. Moreover, the studies demonstrated an increased risk in some areas (eg, breast cancer, venous thromboembolism, biliary tract surgery) and benefits in other areas (eg, a decreased risk of colorectal can-cer, reduction in hip fractures). Within hours of the news releases, pharmacists and physicians were inundated with questions about postmenopausal hormonal therapy from concerned women.
How do we become more effective in keeping up with both published literature and publicized literature? The following tips may help. First, with the advent of the Internet in the last decade, staying in touch with recently published medical/ pharmaceutical literature has become easier. Access to e-TOCs (tables of contents) is a free service provided by most major medical and pharmacy journals. Tracking these publications via e-mail is not time-consuming, because the majority of national/local media stories are usually from a few major US medical journals (eg, JAMA, New England Journal of Medicine). Web sites for health professionals, which are updated frequently, are also useful in tracking down very recent articles of broad interest (eg, drugfacts.com, medscape.com) . When a clinical study is publicized by the media, finding the original publication quickly is essential.
Because mass media presentations are often abbreviated, reading the entire original publication is the second key to understanding its broader implications for patient care. Study design, exclusion criteria, and inclusion criteria are only a few of the factors relevant to applying the study results to a specific patient population.
Most articles in major peer-reviewed journals provide helpful discussions of the study results by identifying limitations in study design, noting unexpected findings, comparing the results with similar research, and suggesting directions for future study.
If a study presents data of significant clinical impact, it is often accompanied by an editorial in the issue. These editorials, often written by individuals with expertise in the study topic, can provide important additional discourse and perspective. Some of the questions raised in editorials can aid in the extrapolation of study results to the clinical setting.
Although controlled clinical studies are scientific in design, their direct application to a specific patient care scenario is rarely an exact science. Nevertheless, the benefit-risk ratio of a particular drug in a specific patient must always be carefully considered, before a change in therapy is made.
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